Elevated lipoprotein(a), hypertension and renal insufficiency as predictors of coronary artery disease in patients with genetically confirmed heterozygous familial hypercholesterolemia

International Journal of Cardiology

Volumn 201, Issue , 2015, Pages 633-638

  Chan, Dick C ^a   Pang, Jing ^a   Hooper, Amanda J ^a,b,c   Burnett, John R ^a,b   Bell, Damon A ^a,b,d   Bates, Timothy R ^a,b   Van Bockxmeer, Frank M ^b,c   Watts, Gerald F ^a,b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b ROYAL PERTH HOSPITAL   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d Lipid Disorders Clinic Cardiometabolic Service Royal Perth Hospital ^*  (Australia)

Author keywords

Cardiovascular disease; Familial hypercholesterolemia; Risk factors

Indexed keywords

APOLIPOPROTEIN B; CREATININE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; DNA;

ADULT; AGE DISTRIBUTION; APOB GENE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; CREATININE BLOOD LEVEL; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; GLOMERULUS FILTRATION RATE; HIGH RISK PATIENT; HUMAN; HYPERLIPOPROTEINEMIA; HYPERTENSION; KIDNEY FAILURE; LDLR GENE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MIDDLE AGED; OBESITY; PCSK9 GENE; PREDICTIVE VALUE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; COMPARATIVE STUDY; COMPLICATION; DNA MUTATIONAL ANALYSIS; FOLLOW UP; GENETIC SCREENING; GENETICS; HETEROZYGOTE; MUTATION; PATHOPHYSIOLOGY; PREVALENCE; PROCEDURES; RETROSPECTIVE STUDY; TIME FACTOR; WESTERN AUSTRALIA;

ADULT; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDIES; DNA; DNA MUTATIONAL ANALYSIS; FEMALE; FOLLOW-UP STUDIES; GENETIC TESTING; GLOMERULAR FILTRATION RATE; HETEROZYGOTE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; HYPERTENSION; LIPOPROTEIN(A); MALE; MIDDLE AGED; MUTATION; PREVALENCE; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; WESTERN AUSTRALIA;

EID: 84943518574     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2015.08.146     Document Type: Article

References (46)

1. J.L. Goldstein, H.H. Hobbs, and M.S. Brown Familial hypercholesterolemia C.R. Scriver, A.L. Beaudet, W.S. Sly, The Metabolic and Molecular Bases of Inherited Disease 2001 McGraw-Hill New York 2863 2913
2. A.K. Soutar, and R.P. Naoumova Mechanisms of disease: genetic causes of familial hypercholesterolemia Nat. Clin. Pract. Cardiovasc. Med. 4 2007 214 225
3. World Health Organization Familial hypercholesterolaemia Report of a Second WHO Consultation 1999 World Health Organization Geneva
4. S.E. Leigh, A.H. Foster, R.A. Whittall, C.S. Hubbart, and S.E. Humphries Update and analysis of the University College London low density lipoprotein receptor familial hypercholesterolemia database Ann. Hum. Genet. 72 2008 485 498
5. E.J.G. Sijbrands, R.G.J. Westendorp, M. Paola Lombardi, and et al. Additional risk factors influence excess mortality in heterozygous familial hypercholesterolaemia Atherosclerosis 149 2000 421 425
6. H.A.W. Neil, V. Seagroatt, D.J. Betteridge, and et al. Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia Heart 90 2004 1431 1437
7. J.S. Hill, M. Hayden, J. Frohlich, and P. Pritchard Genetic and environmental factors affecting the incidence of coronary artery disease in heterozygous familial hypercholesterolemia Arterioscler. Thromb. Vasc. Biol. 11 1991 290 297
8. A.C.M. Jansen, E.S. van Aalst-Cohen, M.W. Tanck, and et al. The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients J. Intern. Med. 256 2004 482 490
9. P.R.W. De Sauvage Nolting, J.C. Defesche, R.J.A. Buirma, B.A. Hutten, P.J. Lansberg, and J.J.P. Kastelein Prevalence and significance of cardiovascular risk factors in a large cohort of patients with familial hypercholesterolaemia J. Intern. Med. 253 2003 161 168
10. R. Alonso, N. Mata, S. Castillo, and et al. Cardiovascular disease in familial hypercholesterolaemia: influence of low-density lipoprotein receptor mutation type and classic risk factors Atherosclerosis 200 2008 315 321
11. N.F. Renna, N. de las Heras, and R.M. Miatello Pathophysiology of vascular remodeling in hypertension Int. J. Hypertens. 2013 2013 808353
12. K. Zandi-Nejad, V.A. Luyckx, and B.M. Brenner Adult hypertension and kidney disease: the role of fetal programming Hypertension 47 2006 502 508
13. M.E. Frischmann, F. Kronenberg, E. Trenkwalder, and et al. In vivo turnover study demonstrates diminished clearance of lipoprotein(a) in hemodialysis patients Kidney Int. 71 2007 1036 1043
14. V. Menon, A. Menon, A. Gul, and M.J. SAarnak Cardiovascular and renal progression factors in chronic kidney disease Kidney Int. 68 2005 1413 1418
15. G. Manjunath, H. Tighiouart, H. Ibrahim, and et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community J. Am. Coll. Cardiol. 41 2003 47 55
16. B.G. Nordestgaard, Chapman Mj, K. Ray, and et al. Lipoprotein(a) as a cardiovascular risk factor: current status Eur. Heart J. 31 2010 2844 2853
17. F. Kronenberg, and G. Utermann Lipoprotein(a): resurrected by genetics J. Intern. Med. 273 2013 6 30
18. P.N. Durrington, J.D. Schofield, T. Siahmansur, and H. Soran Lipoprotein(a): gene genie Curr. Opin. Lipidol. 25 2014 289 296
19. P.N. Hopkins, S. Stephenson, L.L. Wu, W.A. Riley, Y. Xin, and S.C. Hunt Evaluation of coronary risk factors in patients with heterozygous familial hypercholesterolemia Am. J. Cardiol. 87 2001 547 553
20. R. Alonso, E. Andres, N. Mata, and et al. Lipoprotein(a) levels in familial hypercholesterolaemia: an important predictor for cardiovascular disease independent of the type of LDL-receptor mutation J. Am. Coll. Cardiol. 63 2014 1982 1989
21. M.D. Allard, R. Saeedi, M. Yousefi, and J. Frohlich Risk stratification of patients with familial hypercholesterolemia in a multi-ethnic cohort Lipids Health Dis. 13 2014 65
22. O. Wiklund, S.O. Olofsson, G. Fager, and et al. Apolipoprotein(a) and ischaemic heart disease in familial hypercholesterolaemia Lancet 335 1990 1360 1363
23. D.J. Rader, W. Cain, K. Ikewaki, G. Talley, L.A. Zech, D. Usher, and H.B. Brewer Jr. The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate J. Clin. Invest. 93 1994 2758 2763
24. M.L. Koschinsky, and S.M. Marcovina Structure-function relationships in apolipoprotein(a): insights into lipoprotein(a) assembly and pathogenicity Curr. Opin. Lipidol. 15 2004 167 174
25. A.J. Hooper, L.T. Nguyen, J.R. Burnett, and et al. Genetic analysis of familial hypercholesterolaemia in Western Australia Atherosclerosis 224 2012 430 434
26. D.A. Bell, J. Pang, S. Burrows, and et al. Effectiveness of genetic cascade screening for familial hypercholesterolaemia using a centrally co-ordinated clinical service: an Australian experience Atherosclerosis 239 2005 93 100
27. K. Haralambos, S.D. Whatley, R. Edwards, and et al. Clinical experience of scoring criteria for Familial Hypercholesterolaemia (FH) genetic testing in Wales Atherosclerosis 240 2015 190 196
28. P.H. Jones, M.H. Davidson, E.A. Stein, and et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR∗Trial) Am. J. Cardiol. 92 2003 152 160
29. A.S. Levey, J.P. Bosch, J.B. Lewis, T. Greene, N. Rogers, and D. Roth A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group Ann. Intern. Med. 130 1999 461 470
30. D.W. Johnson, G.R.D. Jones, and T.H. Mathew Chronic kidney disease and measurement of albuminuria or proteinuria: a position statement Med. J. Aust. 197 2012 224 225
31. P. Caleb, and L. Santos Jr. Presence and type of low density lipoprotein receptor (LDLR) mutation influences the lipid profile and response to lipid-lowering therapy in Brazilian patients with heterozygous familial hypercholesterolemia Atherosclerosis 233 2014 206 210
32. M. Varret, J.-P. Rabès, G. Collod-Béroud, and et al. Software and database for the analysis of mutations in the human LDL receptor gene Nucleic Acids Res. 25 1997 172 180
33. H.H. Hobbs, D.W. Russell, M.S. Brown, and J.L. Goldstein The LDL receptor in familial hypercholesterolemia: mutational analysis of a membrane protein Annu. Rev. Genet. 24 1990 133 170
34. J. Ferrières, J. Lambert, S. Lussier-Cacan, and J. Davignon Coronary artery disease in heterozygous familial hypercholesterolemia patients with the same LDL receptor gene mutation Circulation 92 1995 290 295
35. M.S. Nenseter, H.W. Lindvig, T. Ueland, and et al. Lipoprotein(a) levels in coronary heart disease-susceptible and -resistant patients with familial hypercholesterolemia Atherosclerosis 216 2011 426 432
36. C.T. Valmadrid, R. Klein, S.E. Moss, and B.E.K. Klein The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus Arch. Intern. Med. 160 2000 1093 1100
37. L.B. Nielsen Atherogenicity of lipoprotein(a) and oxidized low density lipoprotein: insight from in vivo studies of arterial wall influx, degradation and efflux Atherosclerosis 143 1999 229 243
38. N.T. Feric, M.B. Boffa, S.M. Johnston, and M.L. Koschinsky Apolipoprotein(a) inhibits the conversion of Glu-plasminogen to Lys-plasminogen: a novel mechanism for lipoprotein(a)-mediated inhibition of plasminogen activation J. Thromb. Haemost. 6 2008 2113 2120
39. S. Tsimikas, L.D. Tsironis, and A.D. Tselepis New insights into the role of lipoprotein(a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease Arterioscler. Thromb. Vasc. Biol. 27 2007 2094 2099
40. S. Tsimikas, E.S. Brilakis, E.R. Miller, and et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease N. Engl. J. Med. 353 2015 46 57
41. A.D. Mbewu, D. Bhatnagar, P.N. Durrington, and et al. Serum lipoprotein(a) in patients heterozygous for familial hypercholesterolaemia, their relatives and matched control populations Arteriosclerosis 11 1991 940 946
42. E. Leitersdorf, Y. Friedlander, J.M. Bard, J.C. Fruchart, S. Eisenberg, and Y. Stein Diverse effect of ethnicity on plasma lipoprotein[a] levels in heterozygote patients with familial hypercholesterolemia J. Lipid Res. 32 1991 1513 1519
43. J.M. Simó, J. Camps, F. Gómez, N. Ferré, and J. Joven Evaluation of a fully-automated particle-enhanced turbidimetric immunoassay for the measurement of plasma lipoprotein(a). Population-based reference values in an area with low incidence of cardiovascular disease Clin. Biochem. 36 2003 129 134
44. J.C. Hopewell, U. Seedorf, M. Farrall, and et al. Impact of lipoprotein(a) levels and apolipoprotein(a) isoform size on risk of coronary heart disease J. Intern. Med. 276 2014 260 268
45. J. Versmissen, D.M. Oosterveer, M. Yazdanpanah, and et al. A frequent variant in the ABCA1 gene is associated with increased coronary heart disease risk and a better response to statin treatment in familial hypercholesterolemia patients Eur. Heart J. 32 2011 469 475
46. C.G. Maubaret, K.D. Salpea, A. Jain, and et al. Telomeres are shorter in myocardial infarction patients compared to healthy subjects: correlation with environmental risk factors J. Mol. Med. 88 2010 785 794